L. Luciani

TL;DR: First‐line afatinib appears cost‐effective compared with gefitinib for patients with EGFR mutation–positive NSCLCs, and Deterministic and probabilistic sensitivity analyses were conducted.

TL;DR: Since hospitalisation for an acute exacerbation is the most important determinant of future rehospitalisations, management of COPD needs to focus on interventions aimed at decreasing the rehospitalisation risk of in order to lower the burden of disease.

TL;DR: The strongest drivers of preference in French users of inhalation devices for COPD are shape, dose counter and reusability, which are important to patients and should be taken into account by clinicians prescribing these devices.

TL;DR: Based on data from the LUX-Lung 8 trial, afatinib was projected to improve clinical outcomes versus erlotinib, with a 97% probability of being cost-effective assuming a willingness to pay of EUR70,000 per QALY gained, after platinum-based therapy in patients with squamous NSCLC in France.

TL;DR: It is found that nintedanib appears to be a more cost-effective therapeutic option than pirfenidone in a French setting, due to fewer acute exacerbations and a better tolerability profile.